Patients with asymptomatic and mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer had significantly improved radiographic progression-free survival (rPFS) and showed a strong trend for increased overall survival (OS) following treatment with abiraterone acetate plus prednisone compared with prednisone alone, according to second interim analysis results of a study presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with prostate cancer.
After participating in this educational activity, participants should be better able to:
Analyze the impact of abiraterone acetate plus prednisone on pain palliation, delayed pain progression, and delayed time to skeletal-related events.
Integrate new approaches into the management of adults with metastatic castration-resistant prostate cancer.